Kent Christopherson
Head, Global Medical Affairs Orchard Therapeutics
Kent is an accomplished medical affairs leader with >25 years of experience in cell & gene therapy and a proven track record of product launches within rare genetic diseases. He is currently Head of Global Medical Affairs at Orchard Therapeutics. In this role, he leads global medical strategy across both commercial gene therapies and clinical development stage gene therapies, while also supporting early-stage translational research programs. Kent?s personal mission is to accelerate innovation in cell & gene therapy and ensure that breakthrough science reaches the patients who need it the most.
Seminars
Monday 23rd March 2026
Workshop B: Strategic Enterprise Decision-Making, Challenges & Execution for Gene Therapy Expanded Access Programs
11:45 am
- Defining the Strategic Role of Expanded Access Across the Asset Lifecycle
- Structured Decision Framework to Determine Whether and When to Launch EAPs
- Considerations in Execution of Expanded Access Programs
- End to End Expanded Access Program execution processes
Thursday 26th March 2026
Gene Therapies: Global Pathways to Bridge Innovation & Access
3:15 pm
- Enabling early patient access to investigational gene therapies through global pre-approval pathways and compassionate use programs
- Supporting patient access to gene therapy treatment with managed and conditional post-approval models
- Strengthening safety, effectiveness, and global alignment by leveraging multi-stakeholder data and collaboration
